2012-09-30 07:24:35 -
New Pharmaceuticals market report from Datamonitor: "Partnership Models and Emerging Destinations for R&D Outsourcing"
As outsourcing penetration has increased, pharma companies increasingly compete on how efficiently they interact with CROs. Strategic partnerships arose, in part, as a way to reduce the burden of oversight and costs of contracting. The report reviews how leading players are using strategic outsourcing to conduct drug development.
Scope
* The report reviews how leading players are using strategic outsourcing to conduct drug development.
* The scope includes companies providing preclinical and clinical outsourced development services.
Highlights
CROs increasingly position themselves as strategic partners in drug development. Meanwhile, pharma companies are reducing the number of providers they partner with. Tactical outsourcing often brings a cost focus that can lead to compromises on quality; by contrast, strategic outsourcing aligns sponsor and CRO objectives.
Full Report
Details at
-
www.fastmr.com/prod/464861_partnership_models_and_emerging_desti ..
Risk-sharing implies that the sponsor defrays the risk of delays and poor recruitment by incentivizing the CRO with bonus or penalty payments linked to key clinical trial metrics. Alternatively the CRO may agree to receive a percentage of future royalties as part payment, thereby offsetting the sponsor's risk of product failure.
Reasons to Get this Report
* Gain insight into how to most efficiently collaborate with CROs.
* Understand the merits and drawbacks of outsourcing to emerging markets.
Report Table of Contents:
About this report
* Overview
* Strategic scoping and focus
* Contributors
* Data sources and methodology
* Methodology
* Key findings
* CROs are increasingly taking on the risks of drug development
* From transactional to integrated: outsourcing relationships proceed through a series of stages
* Clinical trials activity moving to emerging markets
* China, Brazil, and India lead the growth in clinical trials
* Emerging R&D locations will see the greatest investment and growth
* Jordan, Egypt, and Qatar will lead the growth in R&D in the Middle East
* Pfizer favors the functional service provider model
R&D outsourcing models
* Introduction
* Strategic models by degree of integration
* Transactional (project-by-project) approach
* Preferred provider
* Partnership
* Strategic alliance (risk-sharing)
* Full integration
* Service provision
* Full-service outsourcing
* Functional service providers
* Niche outsourcing
* Relationship management
* Managing successful relationships
* Exit strategies
Emerging outsourcing destinations
* Introduction
* Advantages of offshoring R&D activities
* Preferred offshore R&D activities
* Asia Pacific
* India
* China
* Brazil
* Russia
* Eastern Europe
* Poland
* Czech Republic
* Emerging destinations
* Cuba
* South Korea
* Thailand
* Bulgaria
* Ukraine
* Jordan
* Argentina
* Egypt
* Qatar
* Taiwan
Case studies
* Introduction
* Pfizer: FSP model
* Pfizer: FSP model (second iteration)
* Pfizer: alliance partner model
* Health Decisions: risk-sharing model
* Covance: drug development partnership
* Chorus (Eli Lilly): a fully outsourced model
* BioStorage Technologies: a niche market
Appendix
* Scope
* Methodology
* Glossary/abbreviations
* Bibliography/references
* Disclaimer
TABLES
* Table: Features and characteristics of outsourcing models
* Table: Outsourcing experience across the spectrum of product development
* Table: Characteristics of a successful outsourcing experience
* Table: Comparison of traditional, tactical outsourcing model versus strategic model
* Table: Features and characteristics of outsourcing models
* Table: Characteristics of a strategic partnership
* Table: Advantages and disadvantages to a sponsor of full-service outsourcing
* Table: Benefits of an FSP relationship for the sponsor company
* Table: Potential future opportunities for small CROs
* Table: Factors contributing to the success of a CRO partnership
* Table: Advantages and disadvantages of conducting clinical trials in China
FIGURES
* Figure: Benefits of strategic outsourcing to client and CRO
* Figure: Global patient enrollment, 2000 vs 2006
* Figure: Growth in clinical trials in recently emerged regions, 2007-08 to 2009-10
* Figure: Benefits of strategic outsourcing to client and CRO
* Figure: Outsourcing models in order of increasing integration
* Figure: The importance of size in pharma-CRO relationships
* Figure: Comparison of FSP and full-service models
* Figure: Clinical investigation forms filed in major world regions, 1997-2007
* Figure: Global patient enrollment, 2000 vs. 2006
* Figure: Emerging patient pools of "Western-type" diseases
* Figure: Top candidates for offshore work
* Figure: Annual number of investigative sites per million population, 2006-10
* Figure: Growth in clinical trials in recently emerged regions, 2007-08 to 2009-10
* Figure: Current pharmaceutical R&D capability in India
* Figure: Current pharmaceutical R&D capability in China
About Datamonitor
The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment. View more research from Datamonitor at
www.fastmr.com/catalog/publishers.aspx?pubid=1002
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
For more information about these or related research reports, please visit our website at
www.fastmr.com or call us at 1.800.844.8156.
